Prognostic significance of angiogenic factors in uterine cervical cancer

Anticancer Research

Volumn 31, Issue 8, 2011, Pages 2589-2595

  Landt, Solveig ^a   Wehling, Michael ^b   Heidecke, Harald ^c   Jeschke, Sophia ^d   Korlach, Susanne ^g   Stoblen, Frank ^b   Schmid, Peter ^e   Blohmer, Jens Uwe ^f   Lichtenegger, Werner ^d   Sehouli, Jalid ^d   Kümmel, Sherko ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

^c CellTrend GmbH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

^f Sankt Gertrauden Hospital   (Germany)

^g NONE

Author keywords

Angiogenic factors; Angiogenin; Cervical cancer; Endoglin; VEGF

Indexed keywords

ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; ENDOGLIN; ENDOSTATIN; INTERCELLULAR ADHESION MOLECULE 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ANGIOGENESIS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER STAGING; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SMOKING; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 79961185789     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hakim AA and Dinh TA: Worldwide impact of the human papillomavirus vaccine. Curr Treat Options Oncol 10: 44-53, 2009.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Karimi Zarchi M, Behtash N, Chiti Z and Kargar S: Cervical cancer and HPV vaccines in developing countries. Asian Pac J Cancer Prev 10: 969-974, 2009.
4. Corusić A, Skrgatić L, Mahovlić V, Mandić V, Planinić P and Karadza M: Cervical cancer as a public health issue - what next? Coll Antropol 34: 301-307, 2010.
5. Statistisches Bundesamt: Todesursachen in Deutschland. Gestorbene in Deutschland an ausgewählten Todesursachen 2008. Fachserie 12, Reihe 4. Wiesbaden: Statistisches Bundesamt, 2010.
6. Statistisches Bundesamt: Todesursachen in Deutschland. Gestorbene in Deutschland an ausgewählten Todesursachen 2007. Fachserie 12, Reihe 4. Wiesbaden: Statistisches Bundesamt, 2009.
7. Homer MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG and Edwards B: SEER Cancer Statistics Review, 1975-2006, National Cancer Institute, Bethesda, MD,USA. http://seer.cancer.gov/csr/1975-2006/ based on November 2008 SEER data submission, posted to the SEER web site, 2009.
8. del Campo JM, Prat A, Gil-Moreno A, Perez J and Parera M: Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 110: S72-76, 2008.
9. Fujimoto J: Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas. Anticancer Res 29: 2665-2669, 2009.
10. Kim YH, Kim MA, Park IA, Park WY, Kim JW, Kim SC, Park NH, Song YS and Kang SB: VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival. Gynecol Oncol 119(2): 232-236, 2010.
11. Landt S, Heidecke H, Korlach S, Reuter C, Schwidde I, Barinoff J, Schmid P, Sehouli J and Kümmel S: In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer. Anticancer Res 31: 2609-2616, 2011.
12. Landt S, Heidecke H, Reuter C, Korlach S, Blohmer J-U, Lichtenegger W, Heusner T, Schmid P, Sehouli J, Thill M and Kümmel S: The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer. Anticancer Res 31: 2645-2650, 2011.
13. Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Sehouli J, Lichtenegger W and Kümmel S: Prognostic significance of the angiogenesis factors angiogenin, endoglin and endostatin in uterine cervical cancer. Anticancer Res 31: 2651-2656, 2011.
14. Monk BJ, Willmott LJ and Sumner DA: Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 116: 181-186, 2010.
15. Tewari KS and Monk BJ: Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 36: 170-180, 2009.
16. Willmott LJ and Monk BJ: Cervical cancer therapy: current, future and anti-angiogenesis-targeted treatment. Expert Rev Anticancer Ther 9: 895-903, 2009.
17. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ and Fruehauf JP: Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol 112: 583-589, 2009.
18. Zaghloul MS, El Naggar M, El Deeb A, Khaled H and Mokhtar N: Prognostic implication of apoptosis and angiogenesis in uterine cervical cancer. Int J Radiat Oncol Biol Phys 48: 1409-1415, 2000.
19. Abulafia O, Triest WE and Sherer DM: Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 72: 220-231, 1999.
20. Moore DH: Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 6: 53-57, 2008.
21. Takano M, Kikuchi Y, Kita T, Goto T, Yoshikawa T, Kato M, Watanabe A, Sasaki N, Miyamoto M, Inoue H and Ohbayashi M: Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin. Onkologie 32: 595-597, 2009.
22. Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW and Rader JS: Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103: 489-493, 2006. (Pubitemid 44602157)
23. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE and Roman LD: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 27: 1069-1074, 2009.
24. Tan BR, McLeod HL: Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 32: 113-119, 2005.
25. Ebos JM, Lee CR and Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15: 5020-5025, 2009.
26. Gressett SM and Shah SR: Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43: 490-501, 2009.
27. Randall LM and Monk BJ: Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117: 497-504, 2010.
28. Golshayan AR, Brick AJ and Choueiri TK: Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 4: 85-92, 2008. (Pubitemid 351372609)
29. Hoyt K, Warram JM, Umphrey H, Belt L, Lockhart ME, Robbin ML and Zinn KR: Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med 29: 577-585, 2010.
30. Henriette Tanja L, Guchelaar HJ and Gelderblom H: Pharmacogenetics in chemotherapy of colorectal cancer. Best Pract Res Clin Gastroenterol 23: 257-273, 2009.
31. Norum J, Nieder C and Kondo M: Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J Chemother 22: 75-82, 2010.
32. Zijlmans HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ, Kenter GG and Gorter A: Expression of endoglin (CD105) in cervical cancer. Br J Cancer 100: 1617-1626, 2009.
33. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T and Tokunaga O: Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 56: 717-723, 2006. (Pubitemid 44691157)
34. Carpini JD, Karam AK and Montgomery L: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13: 43-58, 2010.
35. Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, Schonberg SO, Essig M, Vaupel P and van Kaick G: Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 58: 3598-3602, 1998. (Pubitemid 28376557)
36. Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY and Chang HJ: Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 9: 246, 2009.
37. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
38. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239, 2009.
39. Srivastava S, Ramdass B, Nagarajan S, Rehman M, Mukherjee G and Krishna S: Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. Br J Cancer 102: 196-205, 2010.
40. Yang H, Jager MJ and Grossniklaus HE: Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 51: 2835-2842, 2010.
41. Aguilar-Lemarroy A, Romero-Ramos JE, Olimon-Andalon V, Hernandez-Flores G, Lerma-Diaz JM, Ortiz-Lazareno PC, Morgan-Villela G, Del Toro-Arreola S, Bravo-Cuellar A and Jave-Suarez LF: Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related to the risk of developing cervical cancer. BMC Cancer 8: 99, 2008.
42. Kisseljov F, Sakharova O and Kondratjeva T: Cellular and molecular biological aspects of cervical intraepithelial neoplasia. Int Rev Cell Mol Biol 271: 35-95, 2008.
43. Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn HJ, Hamacher J and Boneberg EM: Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94: 524-531, 2006. (Pubitemid 43289756)